A novel vehicle for the treatment of psoriasis

Dattola, Annunziata; Silvestri, Martina; Bennardo, Luigi; Passante, Maria; Rizzuto, Francesco; Dastoli, Stefano; Patruno, Cataldo; Bianchi, Luca; Nisticò, Steven Paul

doi:10.1111/dth.13185

Cited by 31 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is a chronic, noninfectious, relapsing inflammatory skin disease characterized by genetic, immunitary and environmental factors, associated with social discomfort and psychological disorders affecting 1% to 3% of the Caucasian population. 1,2 Various therapies have been proposed for the treatment of psoriasis, from topical treatments based on corticosteroids and vitamin D derivatives to systemic agents and biological drugs 3 In conclusion, the key role of the IL-23/T17 axis in psoriasis, the efficacy maintained over time, the relatively infrequent dosage regimen and its safety profile make Risankizumab a valid therapeutic choice for patients affected by moderate to severe psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising

Dattola

Silvestri

Tamburi

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Risankizumab is a novel anti-interleukin 23 humanized antibody developed to treat severe psoriasis. In this paper, we analyze the key information about this new drug and the results of phase 3 clinical trials already present in literature in order measure its safety and effectiveness in every day practice. Risankizumab seems to be one of the best performing drugs in the treatment of psoriasis, with a good safety profile and a dosage regimen less frequent than all other biologic agents, although head-tohead randomized clinical trials with other anti-interleukin treatments will be necessary in order to confirm these preliminary results.

show abstract

Section: Introductionmentioning

confidence: 99%

Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising

Dattola

Silvestri

Tamburi

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other agents include plant tars (from pine, beech, juniper; concentrations 5–20%), corticosteroids (in creams, ointments, solutions), vitamin D 3 and its derivatives, retinoids (tazarotene 0.05–1% as ointment or gel) [ 1 , 2 , 17 , 18 , 20 , 22 ]. However, the gold standard for topical treatment of psoriasis is a combination of vitamin D derivative and corticosteroids [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Polymeric Gels and Their Application in the Treatment of Psoriasis Vulgaris: A Review

Kulawik‐Pióro

Miastkowska

2021

IJMS

View full text Add to dashboard Cite

Psoriasis is a chronic skin disease, and it is especially characterized by the occurrence of red, itchy, and scaly eruptions on the skin. The quality of life of patients with psoriasis is decreased because this disease remains incurable, despite the rapid progress of therapeutic methods and the introduction of many innovative antipsoriatic drugs. Moreover, many patients with psoriasis are dissatisfied with their current treatment methods and the form with which the drug is applied. The patients complain about skin irritation, clothing stains, unpleasant smell, or excessive viscosity of the preparation. The causes of these issues should be linked with little effectiveness of the therapy caused by low permeation of the drug into the skin, as well as patients’ disobeying doctors’ recommendations, e.g., concerning regular application of the preparation. Both of these factors are closely related to the physicochemical form of the preparation and its rheological and mechanical properties. To improve the quality of patients’ lives, it is important to gain knowledge about the specific form of the drug and its effect on the safety and efficacy of a therapy as well as the patients’ comfort during application. Therefore, we present a literature review and a detailed analysis of the composition, rheological properties, and mechanical properties of polymeric gels as an alternative to viscous and greasy ointments. We discuss the following polymeric gels: hydrogels, oleogels, emulgels, and bigels. In our opinion, they have many characteristics (i.e., safety, effectiveness, desired durability, acceptance by patients), which can contribute to the development of an effective and, at the same time comfortable, method of local treatment of psoriasis for patients.

show abstract

“…Diabetes and its complications may increase direct healthcare expenditures and considerably impact the patient's daily life, family, and social economy. Various dermatological conditions, such as ulcers or psoriasis have been linked to diabetes [3]. Diabetic foot ulcer (DFU) occurs in types 1 and 2 diabetes mellitus and is a common complication of diabetes, i.e., lower limb lesions caused by poor long-term glycemic control [4].…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Medical Resource of Patients with Diabetic Foot Ulcer: A Nationwide Population-Based Retrospective Cohort Study for 2001–2015 in Taiwan

Tai

Hsieh

Lee

et al. 2021

IJERPH

View full text Add to dashboard Cite

Diabetic foot ulcer (DFU) is one of the common complications of diabetes. DFU can cause a huge medical and financial burden due to infections, compromise the quality of life, and increase the mortality rate in patients. However, the consumption of medical resources for DFU is rarely mentioned. A retrospective cohort study was performed. Data were obtained from the National Health Insurance Research Database of Taiwan, and the prevalence and medical utilization data for DFU in 2001–2015 were extracted, followed by the analysis for high-risk populations. Between 2001 and 2015, there were 7511 new DFU patients. A higher proportion in these patients was male, elderly with a low education level, and low income. Between 2001 and 2015, the prevalence of DFU was 0.5–0.8%, and the number of DFU patients showed stable growth. Every year, 12.6–19.3% and 1.2–7.0% of patients underwent debridement and amputation, respectively. The hospitalization fees increased year on year. Our study showed that the DFU prevalence increased year on year, and the DFU medical expenditure increased. DFU tends to occur in males, patients with low socioeconomic status, low education level, those with multiple comorbidities, and old age. Therefore, DFU care and prevention require the entire healthcare system to jointly formulate a prevention plan.

show abstract

A novel vehicle for the treatment of psoriasis

Abstract: This study evaluates the effectiveness of the topical use of an aerosol foam combination of calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam,

Cited by 31 publications

References 15 publications

Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising

Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising

Polymeric Gels and Their Application in the Treatment of Psoriasis Vulgaris: A Review

Prevalence and Medical Resource of Patients with Diabetic Foot Ulcer: A Nationwide Population-Based Retrospective Cohort Study for 2001–2015 in Taiwan

Contact Info

Product

Resources

About